研究单位：[1]Shanghai Hengrui Pharmaceutical Co., Ltd.[2]The Second Affiliated Hospital of Anhui Medical University,Hefei,Anhui,China,230000[3]Beijing Tongren Hospital Affiliated to Capital Medical University,Beijing,China,100005[4]Dongguan people's Hospital,Dongguan,Guangdong,China,523000[5]Nanning Second People's Hospital,Nanning,Guangxi,China,530000[6]The Affiliated Hospital of Guizhou Medical University,Guiyang,Guizhou,China,550000[7]Traditional Chinese Medicine Hospital of Hebei Province,Shijiazhuang,Hebei,China,050000[8]Shiyan Taihe Hospital,Shiyan,Hubei,China,442099[9]the first People's Hospital of Changde,Changde,Hunan,China,415000[10]The Third Xiangya Hospital of Central South University,Changsha,Hunan,China,410000[11]Taizhou People's Hospital,Taizhou,Jiangsu,China,225300[12]Affiliated Zhongshan Hospital of Dalian University,Dalian,Liaoning,China,116001[13]General Hospital of Northern Theater Command,Shenyang,Liaoning,China,110000[14]Central Hospital Affiliated to Shandong First Medical University,Jinan,Shandong,China,250000[15]the First Affiliated Hospital of Xi'An Jiaotong University,Xi'An,Shanxi,China,710061[16]The First Affiliated Hospital of Xi'an Medical University,Xi'an,Shanxi,China,710077[17]Sichuan Provincial People's Hospital,Chengdu,Sichuan,China,610072[18]Jiaxing Second Hospital,Jiaxing,Zhejiang,China,314000[19]Li Huili Hospital of Ningbo Medical Center,Ningbo,Zhejiang,China,315040
研究目的：
The study is being conducted to evaluate the efficacy, and safety of HR18034 for postoperative analgesia in subjects undergoing hemorrhoidectomy. To explore the reasonable dosage of HR18034 for postoperative analgesia in subjects undergoing hemorrhoidectomy.
